Sharib, J., Liu, A., McIntyre, S. M. H., Rhodin, K. E., Kemeny, N. E., Cercek, A., … Lidsky, M. (2023). Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41, pp. 560–560).

Sharib, Jeremy, Annie Liu, Sarah Margaret Helena McIntyre, Kristen Elizabeth Rhodin, Nancy E. Kemeny, Andrea Cercek, James J. Harding, et al. “Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.” In JOURNAL OF CLINICAL ONCOLOGY, 41:560–560, 2023.

Sharib J, Liu A, McIntyre SMH, Rhodin KE, Kemeny NE, Cercek A, et al. Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage. In: JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 560–560.

Sharib, Jeremy, et al. “Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, 2023, pp. 560–560.

Sharib J, Liu A, McIntyre SMH, Rhodin KE, Kemeny NE, Cercek A, Harding JJ, Abou-Alfa GK, Soares K, Wei AC-C, Drebin JA, Kingham TP, D’Angelica MI, Uronis HE, Strickler JH, Morse M, Zani S, Allen PJ, Jarnagin WR, Lidsky M. Adjuvant chemotherapy for resected intrahepatic cholangiocarcinoma confers no survival advantage. JOURNAL OF CLINICAL ONCOLOGY. 2023. p. 560–560.